<H1>Chapter DOI: 10.1007/978-1-60327-829-4_35<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>28</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>28</td></tr><tr><td>BibStructured Count</td><td width="10%">24</td></tr><tr><td>BibUnstructured Count</td><td width="10%">4</td></tr><tr><td>DOI already available in SpringerLink</td><td>17</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>2</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>2</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>2</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_35</td><td>BibArticle</td><td>Fourcroy J. Regulatory history of hormone therapy for prostate cancer. Mol Urol 1998; 2:215&#8211;220</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR2_35</td><td>BibArticle</td><td>Dagher RN, Pazdur R. The role of FDA in the regulation of anticancer drugs. Curr Cancer Ther Rev 2006; 2: 327&#8211;329</td><td><a href=http://dx.doi.org/10.2174/157339406778699196>10.2174/157339406778699196</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_35</td><td>BibChapter</td><td>Roberts Jr. TG. Food and Drug administration role in oncology product development. In Cancer Chemotherapy and Biotherapy: Principles and Practice 4th edition, ed by Chabner BA and Longo DL. Philadelphia, PA, Lippincott Williams &amp; Wilkins, 2006</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4_35</td><td>BibUnstructured</td><td>&lt;number&gt;21&lt;/number&gt;Code of Federal Regulations, Part 314</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5_35</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>FDA Guidance for Industry</span>: <span style='background:#FFD9B3'>clinical trial endpoints for the approval of cancer drugs and biologics</span>. May <span style='background:#66FF66'>2007</span>; <span style='background:#FF3300'>http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6_35</td><td>BibArticle</td><td>Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008; 13: 19&#8211;21</td><td><a href=http://dx.doi.org/10.1634/theoncologist.13-S2-19>10.1634/theoncologist.13-S2-19</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_35</td><td>BibArticle</td><td>Johnson JR, Willimas G, Pazdur R. End points and United States FDA approval of oncology drugs. J Clin Oncol 2003; 21: 1404&#8211;1411</td><td><a href=http://dx.doi.org/10.1200/JCO.2003.08.072>10.1200/JCO.2003.08.072</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_35</td><td>BibArticle</td><td>Rock EP, Kenedy DL, Furness MH, et al. Patient-reported outcomes supporting anticancer product approvals. J Clin Oncol 2007; 25(32): 5094&#8211;5099</td><td><a href=http://dx.doi.org/10.1200/JCO.2007.11.3803>10.1200/JCO.2007.11.3803</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_35</td><td>BibArticle</td><td>Williams G, Pazdur R, Temple R. Assessing tumor-related signs and symptpoms to support cancer drug approval. J Biopharm Stat 2004; 14: 5&#8211;21</td><td><a href=http://dx.doi.org/10.1081/BIP-120028503>10.1081/BIP-120028503</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_35</td><td>BibArticle</td><td>Farrell AT, Papadouli I, Hori A, et al. The advisory process for anticancer drug regulation: a global perspective. Ann Oncol 2006; 17: 889&#8211;896</td><td><a href=http://dx.doi.org/10.1093/annonc/mdj099>10.1093/annonc/mdj099</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_35</td><td>BibArticle</td><td>Dagher R, Johnson J, Willimas G, et al. Accelerated approval of oncology products: a decade of experience. JNCI 2004; 96: 1500&#8211;1509</td><td><a href=http://dx.doi.org/10.1093/jnci/djh279>10.1093/jnci/djh279</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_35</td><td>BibArticle</td><td>Flemming TR. Surrogate endpoints and FDA&#8217;s accelerated approval process. Health Aff 2005; 24: 67&#8211;78</td><td><a href=http://dx.doi.org/10.1377/hlthaff.24.1.67>10.1377/hlthaff.24.1.67</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_35</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>International Conference on Harmonization of techiniqual requirements for registration of pharmaceuticals for human use</span>. <span style='background:#FFD9B3'>Part E9, Statistical principles for clinical trials</span>. <span style='background:#66FF66'>1998</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR14_35</td><td>BibArticle</td><td>Ibrahim A, Scher N, Willimas G, et al. Approval summary for zoledronic acid for treatment of multiple myelopma and cancer bone metastases. Clin Cancer Res 2003; 9: 2392&#8211;2399</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15_35</td><td>BibArticle</td><td>Benson Jr. RC, Murphy GP. Drug therapy of prostate cancer. Urology 1982; 19: 621&#8211;622</td><td><a href=http://dx.doi.org/10.1016/0090-4295(82)90013-9>10.1016/0090-4295(82)90013-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_35</td><td>BibArticle</td><td>Tannock IF, Osaba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756&#8211;1764</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17_35</td><td>BibArticle</td><td>Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the CALGB 9182 study. J Clin Oncol 1999; 17: 2506&#8211;2513</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1097/00005392-199904010-00708>10.1097/00005392-199904010-00708</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Year, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR18_35</td><td>BibArticle</td><td>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. NEJM 2004; 351: 1502&#8211;1512</td><td><a href=http://dx.doi.org/10.1056/NEJMoa040720>10.1056/NEJMoa040720</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_35</td><td>BibArticle</td><td>Dagher R, Li N, Abraham S, et al. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004; 10: 8147&#8211;8151</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-1402>10.1158/1078-0432.CCR-04-1402</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_35</td><td>BibArticle</td><td>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. NEJM 2004; 351: 1513&#8211;1520</td><td><a href=http://dx.doi.org/10.1056/NEJMoa041318>10.1056/NEJMoa041318</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_35</td><td>BibArticle</td><td>Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242&#8211;245</td><td><a href=http://dx.doi.org/10.1200/JCO.2007.12.4008>10.1200/JCO.2007.12.4008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_35</td><td>BibArticle</td><td>Vaishampayan U, Hussain M. Update in systemic therapy of prostate cance: improvement in quality and duration of life. Expert Rev 2008; 8: 269&#8211;281</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23_35</td><td>BibUnstructured</td><td><span style='background:#BDBAD6'>FDA project on cancer drug approval endpoints</span>: <span style='background:#FF3300'>http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/CancerDrugs/ucm094586.htm</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24_35</td><td>BibArticle</td><td>Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 2008; 26: 1148&#8211;1159</td><td><a href=http://dx.doi.org/10.1200/JCO.2007.12.4487>10.1200/JCO.2007.12.4487</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_35</td><td>BibArticle</td><td>Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 3956&#8211;3970</td><td><a href=http://dx.doi.org/10.1200/JCO.2007.11.4769>10.1200/JCO.2007.11.4769</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Year, Author_FamilyName_1, VolumeID, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR26_35</td><td>BibArticle</td><td>Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. JNCI 2006; 98: 516&#8211;521</td><td><a href=http://dx.doi.org/10.1093/jnci/djj129>10.1093/jnci/djj129</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_35</td><td>BibArticle</td><td>Panageas KS, Ben-Porat L, Dickler MN, et al. When you look matters: the effect of assessment schedule on progression-free survival. JNCI 2007; 99: 428&#8211;432</td><td><a href=http://dx.doi.org/10.1093/jnci/djk091>10.1093/jnci/djk091</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_35</td><td>BibArticle</td><td>Wang R, Lagakos SW, Ware JH, et al. Statistics in medicine-reporting of subgroup analyses in clinical trials. NEJM 2007; 357(21): 2189&#8211;2194</td><td><a href=http://dx.doi.org/10.1056/NEJMsr077003>10.1056/NEJMsr077003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>